Get started
Work

Abstract PS3-07-14: Predictors of early discontinuation of adjuvant palbociclib in early HR+/ HER2- breast cancer: final analysis of the PALLAS trial integrating patient-reported outcomes

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps3-07-14
Authors: M. Vetter, A. Wiencierz, M. Gnant, D. Hlauschek, C. Kurzeder, C. Grasic Kuhar, N. Zdenkowski, E. Shinn, J. Suga, D. Egle, J. Meisel, S. Antolin-Novoa, E. Munzone, T. Haddad, S. Loibl, A. Holynskyj, C. Fesl, A. Dueck, A. DeMichele, E. Mayer
Institutions: Kantonsspital Baselland, University Hospital of Basel, Comprehensive Cancer Center Vienna, Austrian Breast & Colorectal Cancer Study Group, Medical University of Vienna, Institute of Oncology Ljubljana, University of Newcastle Australia, The University of Texas MD Anderson Cancer Center, Kaiser Permanente Vallejo Medical Center, Innsbruck Medical University, Universität Innsbruck, Emory University, Winship Cancer Institute, Complexo Hospitalario Universitario A Coruña, European Institute of Oncology, Mayo Clinic, Goethe University Frankfurt, German Breast Group, Pfizer (United States), University of Pennsylvania, Harvard University, Dana-Farber Cancer Institute
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7130692372
Cites:
Cited by:
Related to: